Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Myeloid 1

Conditions

Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Acrocephalosyndactylia 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × pemigatinib × Genitourinary × Clear all
NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
30 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Incyte Corporation

Phase 2 Completed
263 enrolled 20 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡